Quick Answer
Regenerative Medical Technology Group Inc. reported Cash and Equivalents of $530.5 thousand for fiscal year 2023.
Regenerative Medical Technology Group Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2023 | $530.5K | -67.8% |
| 2022 | $1.65M | -44.8% |
| 2021 | $2.98M | +6902.7% |
| 2020 | $42.5K | +81.9% |
| 2019 | $23.4K | -24.2% |
| 2018 | $30.8K | +297.9% |
| 2017 | $7.8K | +16.6% |
| 2016 | $6.6K | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $1.19M | — | -26.5% |
| June 30, 2025 | $1.61M | — | +32.0% |
| March 31, 2025 | $1.22M | +111.1% | +4.9% |
| December 31, 2024 | $1.17M | +119.7% | +101.2% |
| March 31, 2024 | $579.4K | — | +9.2% |
| December 31, 2023 | $530.5K | — | -72.4% |
| June 30, 2022 | $1.92M | -81.7% | -21.8% |
| March 31, 2022 | $2.46M | +212.4% | -17.4% |
- Regenerative Medical Technology Group Inc. showed a decrease of -67.8% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2016–2023 period, Regenerative Medical Technology Group Inc.’s cash and equivalents has grown by 7880.4% (from $6.6 thousand to $530.5 thousand).
- The most recent figure is from Regenerative Medical Technology Group Inc.’s fiscal year 2023 report (Form 10-K), filed with the SEC on April 15, 2024.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: